Wall Street analyst estimates for Incyte Corporation (INCY): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive a...
Valuation Ratios
| P/E Ratio | 15.34 |
| Price / Book | 3.94 |
| EV / EBITDA | 9.23 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.11B | $1.54B | $1.88B | $2.16B | $2.67B | $2.99B | $3.39B | $3.70B | $4.24B | $5.14B |
| Cost of Revenue | $58.2M | $79.5M | $94.1M | $114.2M | $131.3M | $151.0M | $207.0M | $255.0M | $312.1M | $372.1M |
| Gross Profit | $1.05B | $1.46B | $1.79B | $2.04B | $2.54B | $2.84B | $3.19B | $3.44B | $3.93B | $4.77B |
| Research & Development | $581.9M | $1.33B | $1.20B | $1.15B | $2.22B | $1.46B | $1.59B | $1.63B | $2.61B | $2.05B |
| Selling, General & Admin | $303.3M | $366.3M | $434.4M | $468.7M | $516.9M | $739.6M | $1.00B | $1.16B | $1.22B | $1.38B |
| Operating Expenses | $902.5M | $1.70B | $1.66B | $1.64B | $2.80B | $2.25B | $2.60B | $2.79B | $3.83B | $3.43B |
| Operating Income | $145.0M | -$243.4M | $129.2M | $402.0M | -$263.7M | $585.8M | $591.6M | $655.4M | $101.3M | $1.34B |
| EBITDA | $204.6M | -$253.2M | $171.9M | $543.2M | -$178.2M | $630.2M | $599.6M | $919.4M | $408.2M | $1.76B |
| Interest Expense | $38.7M | $6.9M | $1.5M | $1.9M | $2.2M | $1.9M | $2.7M | $2.6M | $2.3M | $2.4M |
| Pre-tax Income | $107.4M | -$312.3M | $115.3M | $486.8M | -$232.2M | $570.4M | $529.1M | $834.2M | $316.6M | $1.66B |
| Income Tax | $3.2M | $852000 | $5.9M | $39.9M | $63.5M | -$378.1M | $188.5M | $236.6M | $284.0M | $377.8M |
| Net Income | $104.2M | -$313.1M | $109.5M | $446.9M | -$295.7M | $948.6M | $340.7M | $597.6M | $32.6M | $1.29B |
| EPS | $0.55 | $-1.53 | $0.52 | $2.08 | $-1.36 | $4.30 | $1.53 | $2.67 | $0.16 | $6.59 |
| EPS (Diluted) | $0.54 | $-1.53 | $0.51 | $2.05 | $-1.36 | $4.27 | $1.52 | $2.65 | $0.15 | $6.41 |
| Shares Outstanding (Diluted) | $194.1M | $204.6M | $215.6M | $217.7M | $218.1M | $222.1M | $224.0M | $225.9M | $210.5M | $200.7M |
Price
| Price | $121.47 |
| Market Cap | $24.6B |
| Exchange | NASDAQ |
| Country | US |
Related companies: BIIB · DGX · GMAB · ILMN · RPRX · THC · UTHR
Explore sector: Healthcare · Biotechnology
More sections of INCY: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks